Wall Street Zen upgraded shares of Genelux (NASDAQ:GNLX – Free Report) from a sell rating to a hold rating in a research note released on Saturday morning.
Other equities research analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Genelux in a report on Monday, March 31st. Benchmark decreased their price objective on shares of Genelux from $25.00 to $23.00 and set a “speculative buy” rating on the stock in a research note on Thursday, May 8th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Genelux presently has an average rating of “Buy” and a consensus price target of $17.75.
View Our Latest Stock Analysis on Genelux
Genelux Stock Performance
Genelux (NASDAQ:GNLX – Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.03. Sell-side analysts forecast that Genelux will post -0.88 EPS for the current year.
Hedge Funds Weigh In On Genelux
A number of institutional investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in shares of Genelux during the fourth quarter valued at approximately $25,000. Advisor Resource Council bought a new position in Genelux in the 1st quarter valued at $34,000. Apollon Wealth Management LLC increased its stake in shares of Genelux by 20.4% in the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after buying an additional 2,857 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Genelux during the fourth quarter valued at $41,000. Finally, Liberty Wealth Management LLC bought a new position in Genelux in the first quarter valued at about $45,000. 37.33% of the stock is owned by institutional investors.
About Genelux
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Featured Articles
- Five stocks we like better than Genelux
- Learn Technical Analysis Skills to Master the Stock Market
- Synopsys Stock Falls on China Ban, But Long-Term Outlook Holds
- Golden Cross Stocks: Pattern, Examples and Charts
- Alphabet Enters a Bull Market: Is It Time to Buy?
- How to Invest in the Best Canadian Stocks
- Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.